Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin

Journal of Physiology and Pharmacology

Volumn 64, Issue 1, 2013, Pages 109-114

  Budzynska, A ^a   Nowakowska Dulawa, E ^a   Marek, T ^a   Boldys, H ^a   Nowak, A ^a   Hartleb, M ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Benign biliary strictures; Cholangiocarcinoma; Neutrophil gelatinase associated lipocalin; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT DILATATION; BILE LEVEL; BILIARY TRACT DRAINAGE; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; VATER PAPILLA TUMOR;

ACUTE-PHASE PROTEINS; BILE; BILE DUCT NEOPLASMS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; CONSTRICTION, PATHOLOGIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; SERUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84875784232     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-875.
2. Khan SA, Emadossadaty S, Ladep N, Thomas HC, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatology 2012; 56: 848-854.
3. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82.
4. Weber A, Schmid RM, Prinz C. Diagnostic approaches for cholangiocarcinoma. World J Gastroenterol 2008; 14: 4131-4136.
5. Weber A, von Weyhern C, Fend F, et al. Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. World J Gastroenterol 2008; 14: 1097-1101.
6. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004; 2: 214-219.
7. Smoczynski M, Jablonska A, Matyskiel A, et al. Routine brush cytology and fluorescence in situ hybridization for assessment of pancreatobiliary strictures. Gastrointest Endosc 2012; 75: 65-73.
8. Seehofer D, Kamphues C, Neuhaus P. Management of bile duct tumors. Expert Opin Pharmacother 2008; 9: 2843-2856.
9. Khan SA, Davidson BR, Goldin RD, Heaton N, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-1669.
10. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 2007; 147: 451-459.
11. Korner T, Kropf J, Hackler R, Brenzel A, Gressner AM. Fibronectin in human bile fluid for diagnosis of malignant biliary diseases. Hepatology 1996; 23: 423-428.
12. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 2009; 25: 279-284.
13. Zabron AA, Horneffer-van der Sluis VM, Wadsworth CA, et al. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol 2011; 106: 1711-1717.
14. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-10432.
15. Bolignano D, Donato V, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010; 288: 10-16.
16. Zhang H, Xu L, Xiao D, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 2007; 60: 555-561.
17. Wang HJ, He XJ, Ma Y Y, et al. Expressions of neutrophil gelatinase-associatedlipocalin in gastric cancer: a potential biomarker for prognosis and an ancillarydiagnostic test. Anat Rec (Hoboken) 2010; 293: 1855-1863.18.
18. Moniaux N, Chakraborty S, Yalniz M, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008; 98: 1540-1547.
19. Hu L, Hittelman W, Lu T, et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009; 89: 531-548.
20. Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis 2010; 27: 295-305.
21. Chan AOO, Chu K-M, Lam SK, et al. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 2005; 104: 740-746.
22. Soyama A, Eguchi S, Takatsuki M, et al. Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 2008; 55: 1390-1393.
23. Leelawat K, Narong S, Wannaprasert J, Leelawat S. Serum NGAL to clinically distinguish cholangiocarcinoma from benign biliary tract diseases. Int J Hepatol 2011; 2011: 873548. DOI: 10.4061/2011/873548.
24. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000; 1482: 298-307.
25. Zerega B, Cermelli S, Michelis B, Cancedda R, Cancedda FD. Expression of NRL/NGAL (neu-related lipocalin/neutrophil gelatinase-associated lipocalin) during mammalian embryonic development and in inflammation. Eur J Cell Biol 2000; 79: 165-172.
26. Jayaraman A, Roberts KA, Yoon J, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol Bioeng 2005; 91: 502-515.
27. Lekstan A, Lampe P, Lewin-Kowalik J, et al. Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) In chronic pancreatitis and pancreatic adenocarcinoma. J Physiol Pharmacol 2012; 63: 589-599.
28. Lim R, Ahmed N, Borregaard N, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 2007; 120: 2426-2434.
29. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002; 160: 1745-1754.
30. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008; 108: 389-397.
31. Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett 1998; 122: 209-214.
32. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 2890-2896.